Clinical trials: Patients with Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study
The IMCY-MS-001 study is a study to test a new experimental drug, IMCY-0141, for the treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS).
- Trial name
- NCT05417269
- Testing
- IMCY-0141, Dimethyl Fumarate
- Where
- Moldova
- Volunteers
- 150 people
- Sponsor
- Imcyse SA
Relapsing-Remitting Multiple Sclerosis, Clinical Isolated Syndrome (CIS)
Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen
To evaluate treatment tolerability, adherence and quality of life (QoL) over 1 year in MS (Multiple Sclerosis) participants who have been switched - due to persistent tolerability issues, particularly injection problems - from a…
- Conditions
- Relapsing-Remitting Multiple Sclerosis, Clinical Isolated Syndrome (CIS), Multiple Sclerosis
- Trial name
- SFERA (NCT02076841)
- Testing
- interferon beta-1a
- Where
- 11 sites in Czechia, Switzerland
- Volunteers
- 40 people
- Sponsor
- Biogen
Multiple Sclerosis
Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis
The primary objective is to assess the activity of nerispirdine in improving the ability to walk, in patients with multiple sclerosis (MS).
- Trial name
- NCT00811902
- Testing
- Nerispirdine
- Where
- 7 sites in United States, Canada and 5 more
- Volunteers
- 405 people
- Sponsor
- Sanofi
Multiple Sclerosis
Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
This research study is being conducted in the U.S. and Europe to evaluate the safety and efficacy of daclizumab for the treatment of multiple sclerosis (MS).
- Trial name
- NCT00109161
- Testing
- Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
- Where
- 36 sites in United States, Canada
- Volunteers
- 270 people
- Sponsor
- PDL BioPharma, Inc.
Multiple Sclerosis, Autoimmune Diseases
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis
The intent of this clinical study is to answer the questions: 1. Is the proposed treatment safe 2. Is treatment effective in improving the disease pathology of patients with Multiple Sclerosis and clinical outcomes?
- Conditions
- Multiple Sclerosis, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Nervous System Diseases
- Trial name
- NCT01453764
- Testing
- Harvesting and Implantation of SVF
- Where
- United States
- Sponsor
- Ageless Regenerative Institute
Bladder Outlet Obstruction, Multiple Sclerosis
GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology
Male self catherterisng observational study.
- Conditions
- Bladder Outlet Obstruction, Multiple Sclerosis, Cauda Equina Syndrome, Enlarged Prostate With Lower Urinary Tract Symptoms
- Trial name
- NCT05470751
- Testing
- Intermittent self-catheterisation
- Where
- 16 sites in United States, France and 1 more
- Volunteers
- 72 people
- Sponsor
- ConvaTec Inc.
Multiple Sclerosis
Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis
The primary objective is to evaluate the feasibility of the Multiple Sclerosis Performance Test (MSPT) in a clinical care setting when used by participants with Multiple Sclerosis (MS).
- Trial name
- NCT03926637
- Testing
- Multiple Sclerosis Performance Test (MSPT)
- Where
- 33 sites in United States, Czechia and 4 more
- Volunteers
- 3,073 people
- Sponsor
- Biogen
Multiple Sclerosis
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who were previously enrolled in a F. Hoffmann-La Roche (Roche) sponsored ocrelizumab phase IIIb/IV trial (i.e.
- Trial name
- NCT03599245
- Testing
- Ocrelizumab
- Where
- 161 sites in Argentina, Belgium and 24 more
- Volunteers
- 1,055 people
- Sponsor
- Hoffmann-La Roche
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
The primary study objective is to test the superiority of Daclizumab High Yield Process (DAC HYP) compared to interferon β 1a (IFN β-1a) in preventing multiple sclerosis (MS) relapse in participants with relapsing remitting…
- Trial name
- (DECIDE) (NCT01064401)
- Testing
- BIIB019 (Daclizumab High Yield Process), Interferon beta-1a
- Where
- 228 sites in United States, Argentina and 26 more
- Volunteers
- 1,841 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis (ALS)
Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)
The overall goal of this research is to delay the respiratory decline of patients with Amyotrophic Lateral Sclerosis (ALS) thereby increasing their lifespan by conditioning the diaphragm with laparoscopically placed electrodes.
- Trial name
- NCT00420719
- Testing
- Intramuscular diaphragm electrodes
- Where
- 8 sites in United States, France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Synapse Biomedical
Multiple Sclerosis
US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector
In this study researchers want to learn more about the medication usage behavior among multiple sclerosis (MS) patients treated with BETASERON using the myBETAapp.
- Trial name
- NCT04356339
- Testing
- Interferon-beta-1b (BETASERON, BAY 86-5046)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Bayer
Multiple Sclerosis
A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment
This is a multi-center, multi-regional observational,24 month study. Health-related quality of life data from the MusiQoL instrument and SF-36 instrument will be collected at baseline, M6, M12, M18 and M24 in patients with MS.
- Trial name
- MusiQoL (NCT00702065)
- Where
- 30 sites in United States, Argentina and 10 more
- Volunteers
- 599 people
- Sponsor
- EMD Serono
ALS, Amyotrophic Lateral Sclerosis
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis
Fosigotifator is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is an up to 156-week, 2-part study.
- Trial name
- NCT04948645
- Testing
- Fosigotifator
- Where
- 14 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- AbbVie
Multiple Sclerosis
Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis
This was a retrospective cohort study utilizing the IQVIA PharMetrics® Plus claims database from 01 August 2019 through 31 May 2022.
- Trial name
- NCT06644638
- Where
- United States
- Volunteers
- 3,632 people
- Sponsor
- Novartis
Multiple Sclerosis
12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients
This is a 12-week study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral CS-0777 in patients with Multiple Sclerosis.
- Trial name
- NCT00616733
- Testing
- CS-0777 tablets
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Daiichi Sankyo
Secondary Progressive Multiple Sclerosis (SPMS)
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)
- Trial name
- REMASTER (NCT07225504)
- Testing
- Remibrutinib (blinded), Remibrutinib (Open label)
- Where
- 296 sites in United States, Argentina and 34 more
- Volunteers
- 1,275 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a 3-part study where Parts A, B (single-blind - investigator and subject blind) will enrol healthy volunteers and Part C (open-label) will enrol RRMS patients.
- Trial name
- NCT01808482
- Testing
- Part A: 100 mg/mL GSK2618960, Part B: Dose of GSK2618960 decided from Part A, Part C: Dose of GSK2618960 decided from Part A and B
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Relapsing Forms of Multiple Sclerosis
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with Relapsing Forms of Multiple Sclerosis (RMS).
- Trial name
- NCT04909502
- Testing
- EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD
- Where
- 4 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Emerald Health Pharmaceuticals
Relapsing Multiple Sclerosis
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab
Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.
- Trial name
- ARTIOS (NCT04353492)
- Testing
- Ofatumumab
- Where
- 123 sites in United States, Argentina and 25 more
- Volunteers
- 562 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis, Multiple Sclerosis
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
- Trial name
- ENABLE (NCT06433752)
- Testing
- No Intervention
- Where
- 113 sites in United States, Puerto Rico and 1 more
- Volunteers
- 2,000 people
- Sponsor
- TG Therapeutics, Inc.